Related Experiment Video

Updated: Jun 21, 2025

Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer
04:20

Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer

Published on: February 9, 2024

918

CDYL loss promotes cervical cancer aggression by increasing PD-L1 expression via the suppression of IRF2BP2

Ying Cui1, Yuxi Zhao2, Guihua Shen1

  • 1Department of Obstetrics and Gynecology, National Center of Gerontology/Beijing Hospital, Beijing 100730, PR China.

Translational Oncology
|July 11, 2024
PubMed
Abstract

Insights

CDYL acts as a tumor suppressor in cervical cancer, inhibiting cancer growth and improving immune response. Its downregulation predicts poor prognosis, suggesting CDYL as a potential biomarker for immunotherapy.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Recurrent or metastatic cervical cancer has poor prognosis (17% 5-year survival) due to limited therapies.
  • CDYL's role in cervical cancer is unexplored, despite its context-dependent function in other cancers.

Purpose of the Study:

  • Investigate CDYL's role in cervical cancer development.
  • Determine CDYL's impact on malignant phenotypes and immune microenvironment.
  • Evaluate CDYL as a predictive biomarker for immunotherapy response.

Main Methods:

  • Analyzed CDYL expression in cervical cancer tissues and cell lines.
  • Performed gain-of-function experiments to assess CDYL/IRF2BP2/PD-L1 axis effects.
  • Validated findings using a mouse model of cervical cancer.

Main Results:

  • CDYL is downregulated in cervical cancer, correlating with poor prognosis.
  • CDYL overexpression suppressed tumor growth, invasion, and reversed immunosuppression by reducing PD-L1.
  • CDYL suppresses PD-L1 via transcriptional inhibition of IRF2BP2.

Conclusions:

  • CDYL is crucial in cervical carcinogenesis and immunotherapy sensitivity.
  • CDYL shows potential as a novel predictive biomarker for cervical cancer immunotherapy response.
Keywords:
CDYLCervical cancerIRF2BP2ImmunotherapyPD-L1

More Related Videos

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

281
Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.2K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.3K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
4.0K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.5K
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.4K